JP2012507033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507033A5 JP2012507033A5 JP2011534536A JP2011534536A JP2012507033A5 JP 2012507033 A5 JP2012507033 A5 JP 2012507033A5 JP 2011534536 A JP2011534536 A JP 2011534536A JP 2011534536 A JP2011534536 A JP 2011534536A JP 2012507033 A5 JP2012507033 A5 JP 2012507033A5
- Authority
- JP
- Japan
- Prior art keywords
- spectrum
- monoclonal antibody
- growth factor
- factor receptor
- epidermal growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 8
- 238000001228 spectrum Methods 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000001819 mass spectrum Methods 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 238000007635 classification algorithm Methods 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000007781 pre-processing Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/321,394 US7858390B2 (en) | 2006-03-31 | 2009-01-20 | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
| US12/321,394 | 2009-01-20 | ||
| PCT/US2009/006267 WO2010085234A1 (en) | 2009-01-20 | 2009-11-20 | Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507033A JP2012507033A (ja) | 2012-03-22 |
| JP2012507033A5 true JP2012507033A5 (enExample) | 2012-05-10 |
| JP4997345B2 JP4997345B2 (ja) | 2012-08-08 |
Family
ID=41571343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534536A Expired - Fee Related JP4997345B2 (ja) | 2009-01-20 | 2009-11-20 | Ｅｇｆｒ経路を標的にする薬物による治療のための結腸直腸癌患者の選択 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7858390B2 (enExample) |
| EP (1) | EP2347261B1 (enExample) |
| JP (1) | JP4997345B2 (enExample) |
| KR (1) | KR101131231B1 (enExample) |
| AU (1) | AU2009338173B2 (enExample) |
| CA (1) | CA2744394A1 (enExample) |
| ES (1) | ES2392805T3 (enExample) |
| IL (1) | IL211944A (enExample) |
| TW (1) | TWI366671B (enExample) |
| WO (1) | WO2010085234A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7736905B2 (en) | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
| US7858390B2 (en) | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
| US7906342B2 (en) * | 2006-03-31 | 2011-03-15 | Biodesix, Inc. | Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples |
| KR101556726B1 (ko) * | 2010-02-24 | 2015-10-02 | 바이오디식스, 인크. | 질량스펙트럼 분석을 이용한 치료제 투여를 위한 암 환자 선별 |
| US8914238B2 (en) | 2011-01-28 | 2014-12-16 | Biodesix, Inc. | Method for predicting breast cancer patient response to endocrine therapy |
| KR102103319B1 (ko) | 2012-06-26 | 2020-04-22 | 바이오디식스, 인크. | 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법 |
| US8718996B2 (en) | 2012-07-05 | 2014-05-06 | Biodesix, Inc. | Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents |
| US10037874B2 (en) | 2014-12-03 | 2018-07-31 | Biodesix, Inc. | Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry |
| CN112710723B (zh) | 2015-07-13 | 2024-11-12 | 佰欧迪塞克斯公司 | 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法 |
| WO2017127679A1 (en) * | 2016-01-21 | 2017-07-27 | Protein Dynamic Solutions Llc | Method and system for spectral data analysis |
| WO2017136139A1 (en) | 2016-02-01 | 2017-08-10 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy |
| WO2017176423A1 (en) | 2016-04-08 | 2017-10-12 | Biodesix, Inc. | Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy |
| WO2018129301A1 (en) * | 2017-01-05 | 2018-07-12 | Biodesix, Inc. | Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups |
| EP3724885A2 (en) | 2017-12-15 | 2020-10-21 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
| EP3773691A4 (en) | 2018-03-29 | 2022-06-15 | Biodesix, Inc. | DEVICE AND METHOD FOR IDENTIFICATION OF PRIMARY IMMUNORESISTANCE IN CANCER PATIENTS |
| WO2022084993A1 (en) * | 2020-10-19 | 2022-04-28 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Rapid and direct identification and determination of urine bacterial susceptibility to antibiotics |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60332639D1 (de) | 2002-08-06 | 2010-07-01 | Univ Johns Hopkins | Verwendung von biomarkern zum nachweis von eierstockkrebs |
| JP2007506442A (ja) | 2003-05-30 | 2007-03-22 | ゲノミック ヘルス， インコーポレイテッド | Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー |
| US20050267689A1 (en) | 2003-07-07 | 2005-12-01 | Maxim Tsypin | Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications |
| US20050048547A1 (en) | 2003-07-17 | 2005-03-03 | Hongyu Zhao | Classification of disease states using mass spectrometry data |
| WO2005098445A2 (en) | 2004-03-30 | 2005-10-20 | Eastern Virginia Medical School | Lung cancer biomarkers |
| US20060029574A1 (en) | 2004-08-06 | 2006-02-09 | Board Of Regents, The University Of Texas System | Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity |
| SI1913157T2 (sl) * | 2005-06-28 | 2017-02-28 | Genentech, Inc. | EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem |
| US7908091B2 (en) * | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| US7736905B2 (en) * | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
| US7858390B2 (en) | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
-
2009
- 2009-01-20 US US12/321,394 patent/US7858390B2/en not_active Expired - Fee Related
- 2009-11-20 KR KR1020117007641A patent/KR101131231B1/ko not_active Expired - Fee Related
- 2009-11-20 AU AU2009338173A patent/AU2009338173B2/en not_active Ceased
- 2009-11-20 EP EP09795836A patent/EP2347261B1/en not_active Not-in-force
- 2009-11-20 ES ES09795836T patent/ES2392805T3/es active Active
- 2009-11-20 WO PCT/US2009/006267 patent/WO2010085234A1/en not_active Ceased
- 2009-11-20 JP JP2011534536A patent/JP4997345B2/ja not_active Expired - Fee Related
- 2009-11-20 CA CA2744394A patent/CA2744394A1/en not_active Abandoned
- 2009-12-16 TW TW098143181A patent/TWI366671B/zh not_active IP Right Cessation
-
2011
- 2011-03-24 IL IL211944A patent/IL211944A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513728A5 (enExample) | ||
| Onaitis et al. | Prediction of long-term survival after lung cancer surgery for elderly patients in The Society of Thoracic Surgeons General Thoracic Surgery Database | |
| Quezada et al. | Omics-based biomarkers: current status and potential use in the clinic | |
| Lima et al. | Segregation of ovarian cancer stage exploiting spectral biomarkers derived from blood plasma or serum analysis: ATR‐FTIR spectroscopy coupled with variable selection methods | |
| JP2011506917A5 (enExample) | ||
| JP2015528110A5 (enExample) | ||
| JP2013520681A5 (enExample) | ||
| IL204922A0 (en) | Methods for detecting major adverse cardiovascular and cerebrovascular events | |
| WO2008127376A3 (en) | Biological cell sorting and characterization using aerosol mass spectrometry | |
| WO2007109881A8 (en) | Biomarkers useful for diagnosing prostate cancer, and methods thereof | |
| BR0312534A (pt) | método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura | |
| WO2012047899A3 (en) | Novel dna hypermethylation diagnostic biomarkers for colorectal cancer | |
| WO2012153326A1 (en) | Diagnosis of cancer | |
| GB2494580A (en) | Method for diagnosing lung cancer | |
| JP2011516046A5 (enExample) | ||
| JP2009534667A5 (enExample) | ||
| WO2009074276A3 (en) | Marker panel for colorectal cancer | |
| Mazzone et al. | Progress in the development of volatile exhaled breath signatures of lung cancer | |
| WO2015100459A3 (en) | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies | |
| CN106092990A (zh) | 一种宁夏枸杞的三维荧光光谱鉴别方法 | |
| WO2010037859A3 (en) | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family | |
| Yang et al. | Decreased macrophage inflammatory protein (MIP)‐1α and MIP‐1β increase the risk of developing nasopharyngeal carcinoma | |
| Xu et al. | Serum analysis method combining cellulose acetate membrane purification with surface‐enhanced Raman spectroscopy for non‐invasive HBV screening | |
| WO2005031301A3 (en) | Raman signature probes and their use in the detection and imaging of molecular processes and structures | |
| Michalčíková et al. | A selected ion flow tube study of the ion molecule association reactions of protonated (MH+), nitrosonated (MNO+) and dehydroxidated (M− OH)+ carboxylic acids (M) with H2O |